~~<i id='7D1C2CE31D'><strike id='7D1C2CE31D'><tt id='7D1C2CE31D'><pre id='7D1C2CE31D'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：hotspot 2025-09-29 08:47:16 Page View：6541

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Louisiana bill approved classifying abortion pills as controlled substances
Next article： Tori Bowie and the unacceptable rates of Black maternal death

comprehensive

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Lawsuit challenges CMS nursing home minimum staffing rule

JeffChiu/APAnewfederallawsuitchallengingtheBidenadministration’snewminimumnursinghomestaffingrulelay

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

When prostate cancer spreads, where it goes matters

Prostatecancercellsseenunderthemicroscope.NIHProstatecancertendstobethetortoiseoftumors,growingandsp